Tools

LEADER 02785cam a22005895i 4500

001 ssj0002845261;

003 WaSeSS;

005 20250212121027.0;

006 m d ;

007 cr n ;

008 180508s2019 ne s 001 0 eng d;

010 a| 2018943830;

015 a| GBB8L27632| bnb;

016 7 a| 0191310892| Uk;

020 a| 9780081026618q| (pbk.);

020 a| 0081026617q| (pbk.);

020 z| 9780081026625 (ePub ebook);

035 a| (WaSeSS)ssj0002845261;

042 a| lccopycat;

049 a| EREEa| NEHH;

050 00 a| RS431.A64b| P38 2019;

082 04 a| 615.7982| 23;

100 1 a| Patel, Harun M.?| UNAUTHORIZED;

245 10 a| Third generation EGFR inhibitorsh| [electronic resource] :b| overcoming EGFR resistance and toxicity problems /c| Harun M. Patel, R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India, Rahul Pawara, .C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India, Sanjay J. Surana, .C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India.;

260 a| Amsterdam :b| Elsevier,c| [2019];

300 a| xx, 188 pages ;c| 23 cm;

500 a| Includes index.;

506 a| Available only to authorized users.;

538 a| Mode of access: World Wide Web;

650 0 a| Antineoplastic agentsx| Therapeutic use.=| ^A1221;

650 0 a| Cancerx| Treatment.=| ^A13628;

650 0 a| Epidermal growth factor.=| ^A1379995;

650 2 a| Epidermal Growth Factor=| ^A946074;

650 6 a| Anticancéreuxx| Emploi en thérapeutique.;

650 6 a| Cancerx| Traitement.;

650 6 a| Facteur de croissance épidermique.;

650 7 a| Antineoplastic agentsx| Therapeutic use.2| fast0| (OCoLC)fst00810609;

650 7 a| Cancerx| Treatment.2| fast0| (OCoLC)fst00845538;

650 7 a| Epidermal growth factor.2| fast0| (OCoLC)fst00914115;

655 0 a| Electronic books.=| ^A491897;

776 08 i| ebook version :z| 9780081026625;

856 40 z| Full text available from eBook - Chemistry 2019u| https://go.openathens.net/redirector/ecu.edu?url=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Fbook%2F9780081026618;

947 a| (OCoLC)on1079801562;

949 a| CLICK ON WEB ADDRESSw| ASISh| JOYNER188;

949 a| CLICK ON WEB ADDRESSw| ASISh| HSL77;

949 a| CLICK ON WEB ADDRESSw| ASISh| JMUSIC60;

596 a| 1 3 4;

998 a| 6203133;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6203133-1001l| JNETm| JOYNERr| Ys| Yt| JNESSBKu| 7/21/2023x| EBOOKz| JERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6203133-2001l| HSLELECm| HSLr| Ys| Yt| HEBKu| 7/21/2023x| EBOOKz| HERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6203133-3001l| MNETm| JMUSICr| Ys| Yt| MNESSBKu| 7/21/2023x| EBOOKz| JERESOURCE;

Third generation EGFR inhibitors overcoming EGFR resistance and toxicity problems / Harun M. Patel, R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India, Rahul Pawara, .C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India, Sanjay J. Surana, .C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India.

Author/creator	Patel, Harun M.
Format	Electronic
Publication Info	Amsterdam : Elsevier, [2019]
Description	xx, 188 pages ; 23 cm
Supplemental Content	Full text available from eBook - Chemistry 2019
Subjects	Antineoplastic agents--Therapeutic use. Cancer--Treatment. Epidermal growth factor. Epidermal Growth Factor Anticancéreux--Emploi en thérapeutique. Cancer--Traitement. Facteur de croissance épidermique.

General note	Includes index.
Access restriction	Available only to authorized users.
Technical details	Mode of access: World Wide Web
Issued in other form	ebook version : 9780081026625
Genre/form	Electronic books.
LCCN	2018943830
ISBN	9780081026618 (pbk.)
ISBN	0081026617 (pbk.)

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

Click here for more information about this title

Availability